The Union Budget 2026–27, presented by the government, has taken a landmark step toward making high-cost cancer drugs and rare disease treatments more affordable while simultaneously strengthening India’s healthcare infrastructure and biopharma innovation ecosystem. The Budget emphasizes a patient-centric approach, balancing immediate relief for those requiring life-saving therapies with long-term investments in regulatory reforms, clinical trials, and domestic manufacturing. By removing basic customs duties on 17 expensive cancer drugs, including Ribociclib, Venetoclax, Ibrutinib, Ponatinib, Dabrafenib, Trametinib, Toripalimab, and Ipilimumab, as well as seven rare disease drugs, the government has aimed to reduce the landed cost of imported medicines significantly. This measure ensures that advanced medical treatments become more accessible to patients across India while simultaneously promoting innovation and growth within the domestic pharmaceutical sector. Experts have welcomed this decision, noting that it not only addresses affordability but also aligns India with global healthcare standards, helping patients access therapies that previously cost between Rs 20,000 and Rs 1.5 lakh per month.
The Budget also focuses on broader healthcare reforms, including expanding the country’s clinical research infrastructure and aligning India’s drug regulatory framework with international benchmarks. By establishing a national network of 1,000 accredited clinical trial sites, the government intends to accelerate research approvals, ensure higher predictability in regulatory timelines, and strengthen the approval ecosystem through specialized scientific review teams. These initiatives, combined with regulatory reforms led by the Central Drugs Standard Control Organization (CDSCO), are designed to enhance India’s position as a global leader in biopharmaceutical research and innovation while ensuring that domestic patients benefit from high-quality, timely medical interventions.
Customs Duty Reforms and Patient-Centric Healthcare Initiatives
The removal of basic customs duties on select high-cost medications and foods for special medical use represents a transformative step in India’s healthcare policy. Historically, imported medicines attracted duties ranging from 5% to 11%, making life-saving treatments prohibitively expensive for many patients. By eliminating these duties for 17 critical cancer drugs and seven rare disease treatments, the government has effectively lowered the financial barrier to essential therapies, providing relief for patients and their families. Healthcare leaders, including Bhansu Prakash Kalmath of Grant Thornton Bharat, have described this move as a major step toward equitable healthcare, emphasizing its importance for patients who rely on costly imported medications. Sharvil Patel of Zydus Lifesciences noted that exempting these drugs from customs duty would enhance patient access and address urgent needs in accessibility, affordability, and patient-centered care.
This policy reform is particularly significant in Tier 2 and Tier 3 cities, where access to specialized care has traditionally been limited, and lifestyle-related diseases are rising. By reducing costs and expanding accessibility, the government aims to bridge disparities in healthcare availability across different regions. The customs duty exemption complements other budgetary initiatives, ensuring that patients not only have access to life-saving drugs but also benefit from improved affordability. Furthermore, by emphasizing patient-centric healthcare policies, the government signals its commitment to integrating public health priorities into fiscal planning while enhancing social equity in access to treatments.
The Budget also addresses the broader challenge of ensuring the availability of advanced therapies through strategic investments in healthcare infrastructure. By strengthening clinical trial capabilities and encouraging domestic production, India can reduce dependence on imports in the long term while ensuring that new therapies are both safe and affordable. These reforms, experts suggest, represent a thoughtful approach to addressing healthcare challenges comprehensively, balancing short-term affordability with long-term systemic improvements.
Strengthening Biopharma Innovation and Research Ecosystem
Beyond immediate affordability measures, the Union Budget 2026–27 places a strong emphasis on creating a globally competitive biopharma ecosystem. The government has committed Rs 10,000 crore toward the Biopharma SHAKTI initiative, which aims to enhance India’s research and development capabilities, expand clinical trial infrastructure, and strengthen regulatory predictability. By creating 1,000 accredited clinical trial sites, the government seeks to ensure faster approvals, higher compliance with global standards, and a stronger platform for domestic and international collaboration in pharmaceutical innovation. Biocon chairperson Kiran Mazumdar-Shaw emphasized that these investments, alongside the expansion of NIPER institutions and regulatory strengthening, reflect a deep understanding of the requirements to compete globally while maintaining quality and safety.
The Budget also unveiled a Rs 1.1 lakh crore health allocation, representing a 9% increase from the previous fiscal year, underscoring the government’s commitment to both routine and specialized healthcare. These allocations are designed to support public health initiatives, improve infrastructure, and foster technological innovation, ensuring that India’s healthcare system is prepared to meet both current and future challenges. Experts note that such investments will help India position itself as a hub for biopharmaceutical manufacturing, research, and clinical trials, facilitating faster and more reliable delivery of therapies to patients.
Moreover, the regulatory reforms embedded in the Budget aim to streamline approval pathways for generics, biosimilars, and advanced therapies, improving both quality assurance and access. Gopa Nair of the Working Group on Access to Medicines emphasized that relying on customs duty exemptions, rather than solely deploying legal tools like compulsory licensing, allows the government to indirectly enhance affordability while preserving regulatory integrity. These steps collectively strengthen the healthcare system, ensuring patients benefit from both cost reduction and increased access to high-quality treatments.
The Biopharma SHAKTI initiative, in particular, represents a strategic effort to align India’s domestic biopharma sector with global standards, fostering innovation and improving regulatory predictability. By integrating clinical trials, manufacturing support, and regulatory reforms, the program provides a comprehensive framework to enhance India’s competitiveness in the global pharmaceutical market. Sameer Sah of Khaitan & Co highlighted that these initiatives are pivotal in creating a strong policy foundation for the healthcare sector, ensuring that capacity expansion is coupled with high-quality standards, thereby facilitating global collaborations and research partnerships.
Through these measures, the Union Budget 2026–27 aims to create a sustainable, innovation-driven healthcare ecosystem capable of addressing both present challenges and long-term strategic objectives. Patients benefit immediately from reduced costs and improved access to advanced therapies, while the healthcare and biopharma sectors gain from enhanced infrastructure, streamlined regulations, and expanded research capacity. The Budget thus integrates social welfare objectives with economic and scientific priorities, ensuring a holistic approach to national health policy.
Additionally, the Budget emphasizes the importance of clean, sustainable, and technology-driven healthcare solutions. Investments in clinical trial infrastructure, research, and manufacturing not only improve patient outcomes but also enable India to participate actively in global healthcare innovation. By prioritizing affordability, accessibility, and regulatory efficiency, the government seeks to create a healthcare system that is equitable, efficient, and capable of sustaining long-term innovation. The combination of immediate relief measures for patients and strategic support for research and industry reflects a comprehensive vision for India’s healthcare sector.
The Union Budget 2026–27 also demonstrates the government’s recognition of the critical role of strategic partnerships, international standards, and global competitiveness in healthcare. By improving regulatory processes and expanding accredited clinical trial sites, India is aligning itself with global best practices while creating opportunities for domestic innovation. These efforts are designed to make advanced therapies accessible to Indian patients while fostering a research ecosystem capable of producing globally competitive medical solutions. Experts believe that these reforms will significantly enhance India’s capacity for drug development, clinical research, and biopharmaceutical manufacturing, positioning the country as a global healthcare hub.
In essence, the Union Budget 2026–27 balances immediate patient needs with long-term strategic healthcare objectives. By removing customs duties, expanding clinical trials, strengthening regulatory frameworks, and investing in biopharma innovation, the government has charted a course toward a more accessible, affordable, and globally competitive healthcare ecosystem. Patients, healthcare providers, and the pharmaceutical industry all stand to benefit from this multi-faceted approach, which combines cost relief, policy reforms, and strategic investment to enhance both outcomes and capacity.
The comprehensive measures in the Budget reflect a patient-first philosophy while addressing systemic challenges in India’s healthcare system. By linking affordability, accessibility, and innovation, the government ensures that patients receive timely treatment, that domestic healthcare and biopharma sectors remain competitive, and that India’s healthcare infrastructure is prepared for future growth. Experts have lauded the Budget for its forward-looking vision, combining short-term relief for patients with long-term reforms aimed at strengthening the research, manufacturing, and regulatory ecosystem in the country.
With a clear focus on reducing costs, expanding access, and promoting innovation, the Union Budget 2026–27 signals a transformative moment for India’s healthcare sector. By integrating fiscal incentives, infrastructure development, clinical research expansion, and regulatory predictability, the government is positioning India as a leader in patient-centric healthcare and biopharmaceutical innovation. The Budget represents a holistic approach to healthcare policy that prioritizes affordability, quality, and sustainability, while simultaneously enabling India to compete effectively in the global medical and research landscape.
Through these measures, India aims to achieve a healthcare ecosystem that is resilient, innovative, and equitable, ensuring that life-saving drugs, advanced therapies, and medical innovations are accessible to all segments of society. The combination of patient-focused relief and systemic reforms reflects a broader vision of strengthening India’s healthcare capabilities and fostering sustainable growth in the medical and biopharma sectors. The Union Budget 2026–27 thus lays a foundation for transformative changes in the healthcare landscape, addressing both immediate patient needs and the strategic requirements of a globally competitive healthcare system.
